The Global Antibiotic Research & Development Partnership (GARDP) and Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ:INVA), announced positive results from a Phase 3 trial of zoliflodacin, a first-in-class oral antibiotic for treating uncomplicated gonorrhea. The study met its primary endpoint, demonstrating statistical non-inferiority of microbiological cure at the urogenital site compared to the current standard of care. The success of this study could change how physicians approach gonorrhea infections, offering an oral alternative to injections, improving patient access and compliance, and helping reduce the spread of antibiotic-resistant strains.